Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02760498

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Advanced Cutaneous Squamous Cell Carcinoma Clinical Trial

Official title:
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Clinical Trial Summary

Groups 1 to 4 To estimate the clinical benefit of cemiplimab monotherapy for patients with: metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable locally advanced CSCC Group 6 To provide additional efficacy and safety data for cemiplimab monotherapy in patients with advanced CSCC (metastatic [nodal or distant] or locally advanced treated with cemiplimab

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02760498
Study type Interventional
Source Regeneron Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date April 7, 2016
Completion date October 18, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03834233 - Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT04050436 - Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer Phase 2
Active, not recruiting NCT04807777 - Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Phase 2
Terminated NCT04611321 - Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma Phase 1/Phase 2